Additional file 3 of Development of a pharmacoeconomic registry: an example using hormonal contraceptives
收藏数据链接：
官方服务：
资源简介：
Additional file 3.
应用场景：
创建时间：
2021-03-20
相关数据集
Reduced heart failure-related healthcare costs with Furoscix versus in-hospital intravenous diuresis in heart failure patients: the FREEDOM-HF study - supplementary table
Aim: Compare heart failure (HF) costs of Furoscix use at home compared with inpatient intravenous (IV) diuresis. Patients & methods: Prospective, case control study of chronic HF pat
DataCite Commons2024-05-17 更新100
Table 1_Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis.docx
IntroductionRemdesivir (RDV) and nirmatrelvir/ritonavir (NRM/RTV) are two antiviral agents for treating outpatient adults with mild to moderate symptomatic COVID-19 at high risk of developing a severe
NIAID Data Ecosystem10
The heterogeneity in the cost per case avoided with coxibs stratified by the number of major risk factors and exposure characteristics (with the cost per case avoided estimated for each individual prescription).
#Each NSAID prescription was classified according to first-ever use, long gap (previous prescription at least 6 mo before), and short gap (previous prescription within the last 6 mo). The medication p
Figshare2015-12-02 更新10
Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study
ABSTRACT BACKGROUND: Lung cancer is the fourth most common cancer in Brazil. In the 2000s, better understanding of molecular pathways led to development of epidermal growth factor receptor (EGFR)-ta
NIAID Data Ecosystem20
Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.
Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.
Figshare2018-07-18 更新10
